TELA Bio prices $13 million stock offering at $1.11 per share

TELA Bio Inc. announced the pricing of an underwritten registered direct offering totaling approximately $13.0 million in gross proceeds. The medical technology company will sell 4,189,000 shares of common stock at $1.11 per share and pre-funded warrants to purchase 7,523,000 shares at $1.1099 per warrant.

The offering was led by Nantahala Capital and EW Healthcare Partners, with Canaccord Genuity serving as sole bookrunner. The transaction is expected to close on or around November 17, 2025, subject to customary closing conditions.

TELA Bio, based in Malvern, Pennsylvania, develops soft-tissue reconstruction solutions for surgical applications. The company plans to use net proceeds for general corporate purposes, including sales and marketing, research and development activities, administrative matters, working capital and capital expenditures.

The pre-funded warrants carry an exercise price of $0.0001 per share. The gross proceeds figure assumes no exercise of the pre-funded warrants prior to closing.

The offering is conducted under a shelf registration statement on Form S-3 that became effective with the Securities and Exchange Commission in November 2023. A preliminary prospectus supplement has been filed with the SEC, with a final prospectus supplement containing complete terms expected to follow.

You May Also Be Interested In

• Arbe Robotics prices $15M direct offering at $0.60 per share
• Sysco closes C$1.5 billion senior notes offering for Jetro acquisition
• IBG resolves Nasdaq filing issue but faces equity shortfall